Emerging drugs for osteoarthritis

Bibliography

• Zebrowski M. The Pain Market Outlook to 2011. Business Insights Ltd; 2005
   Google Scholar
• Stakeholder Opinions: Osteoarthritis, Datamonitor; 2006. p. 17
   Google Scholar
• Available from: http://www.cdc.gov/nccdphp/arthritis
   Google Scholar
• Gabriel SE, Crowson CS, O'Fallon WM. The epidemiology of rheumatoid arthritis in Rochester, Minnesota. Arthritis Rheum 1999;42(3):415-20; NINDS/NIH 1999; NIDDK/NIH 2003
   PubMed Web of Science ®Google Scholar
• NINDS/NIH 1999 (migraine)
   Google Scholar
• Wieland HA, Michaelis M, Kirschbaum BJ, Osteoarthritis – an untreatable disease? Nat Rev Drug Discov 2005;4(4):331-44
   PubMed Web of Science ®Google Scholar
• Reijman M, Bierma-Zeinstra SM, Pols HA, Is there an association between the use of different types of nonsteroidal antiinflammatory drugs and radiologic progression of osteoarthritis? The Rotterdam Study. Arthritis Rheum 2005;52(10):3137-42
   PubMed Web of Science ®Google Scholar
• Wood JN. Nerve growth factor and pain. N Engl J Med 2010;363:1572-3 Comment on Discussion section of reference 9 below
   PubMed Web of Science ®Google Scholar
• Lane NE, Schnitzer TJ, Birbara CA, Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med 2010;363(16):1521-31
   PubMed Web of Science ®Google Scholar
• Nuesch E, Rutjes AW, Trelle S, Doxycycline for osteoarthritis of the knee or hip. Cochrane Database Syst Rev 2009;7(4):CD007323
   Google Scholar
• Brandt KD, Mazzuca SA, Katz BP, Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, bouble-blind trial. Arthritis Rheum 2005;52:2015-25
   PubMed Web of Science ®Google Scholar
• Felson DT, Chaisson CE, Hill CL, The association of bone marrow lesions with pain in knee osteoarthritis. Ann Intern Med 2001;134(7):541-9
   PubMed Web of Science ®Google Scholar
• Hill CL, Gale DG, Chaisson CE, Knee effusions, popliteal cysts, and synovial thickening: association with knee pain in osteoarthritis. J Rheumatol 2001;28(6):1330-7
   PubMed Web of Science ®Google Scholar
• Hill CL, Hunter DJ, Niu J, Synovitis detected on magnetic resonance imaging and its relation to pain and cartilage loss in knee osteoarthritis. Ann Rheum Dis 2007;66(12):1599-603
   PubMed Web of Science ®Google Scholar
• Chevalier X, Goupille P, Beaulieu AD, Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2009;61(3):344-52
   PubMed Web of Science ®Google Scholar
• Malemud CJ. Anticytokine therapy for osteoarthritis: evidence to date. Drugs Aging 2010;27(2):95-115
   PubMed Web of Science ®Google Scholar
• Westacott CI, Whicher JT, Barnes IC, Synovial fluid concentration of five different cytokines in rheumatic diseases. Ann Rheum Dis 1990;49(9):676-81
   PubMed Web of Science ®Google Scholar
• Bertazzolo N, Punzi L, Stefani MP, Interrelationships between interleukin (IL)-1, IL-6 and IL-8 in synovial fluid of various arthropathies. Agents Actions 1994;41(1-2):90-2
   PubMedGoogle Scholar
• Brenner SS, Klotz U, Alscher DM, Osteoarthritis of the knee - clinical assessments and inflammatory markers. Osteoarthritis Cartilage 2004;12(6):469-75
   PubMed Web of Science ®Google Scholar
• Zhang W, Moskowitz RW, Nuki G, OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008;16(2):137-62
   PubMed Web of Science ®Google Scholar
• American College of Rheumatology guidelines on the treatment of osteoarthritis; 1997
   Google Scholar
• Peoplemetrics Patient Segmentation Research 2007
   Google Scholar
• National Council on Aging, Harris Interactive Survey 2005
   Google Scholar
• Read SJ, Dray A. Osteoarthritic pain: a review of current, theroretical, and emerging therapeutics. Expert Opin Investig Drugs 2008;17(5):619-40
   PubMed Web of Science ®Google Scholar
• Hunter DJ. Pharmacologic therapy for osteoarthritis – the era of disease modification. Nat Rev Rheumatol 2011;7(1):13-22
   PubMed Web of Science ®Google Scholar
• Hunter DJ, Hellio Le Graverand-Gastineau MP. How close are we to having structure modifying drugs available? Rheum Dis Clin North Am 2008;34(3):789-802
   PubMed Web of Science ®Google Scholar
• Baerwald C, Verdecchia P, Duquesroix B, Efficacy, safety, and effects on blood pressure of naproxcinod 750 mg twice daily compared with placebo and naproxen 500 mg twice daily in patients with osteoarthritis of the hip: a randomized, double-blind, parallel-group, multicenter study. Arthritis Rheum 2010;62(12):3635-44
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ, Kivitz A, Frayssinet H, Efficacy and safety of naproxcinod in the treatment of patients with osteoarthritis of the knee: a 13-week prospective, randomized, multicenter study. Osteoarthritis Cartilage 2010;18(5):629-39
   PubMed Web of Science ®Google Scholar
• Wild JE, Grond S, Kuperwasser B, Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract 2010;10(5):416-27
   PubMed Web of Science ®Google Scholar
• Iyengar S, Webster AA, Henrick-Lucke SK, Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine inhibitor in persistent pain models in rats. J Pharmacol Exp Ther 2004;311:576-84
   PubMed Web of Science ®Google Scholar
• Wong DT, Bymaster FP. Dual serotonin and noradrenaline uptake inhibitor class of antidepressants—potential for greater efficacy or just hype? Prog Drug Res 2002;58:169-222
   PubMedGoogle Scholar
• Chappell AS, Desaiah D, Liu-Seifert H, A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee. Pain Pract 2011;11(1):33-41
   PubMed Web of Science ®Google Scholar
• Spector TD, Conaghan PG, Buckland-Wright JC, Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized controlled trial. Arthritis Res Ther 2005;7:R625-33
   PubMed Web of Science ®Google Scholar
• Rosenbaum T, Simon SA. TRPV1 receptors and signal transduction. In: Liedtke WB, Heller S, editors, TRP ion channel function in sensory transduction and cellular signaling cascades. Chapter 5. CRC Press, Boca Raton (FL); 2007. Frontiers in Neuroscience
   Google Scholar
• Cesare P, Dekker LV, Sardini A, Specific involvement of PKC-epsilon in sensitization of the neuronal response to painful heat. Neuron 1999;23:617-24
   PubMed Web of Science ®Google Scholar
• Premkumar LS, Ahern GP. Induction of vanilloid receptor channel activity by protein kinase C. Nature 2000;408:985-90
   PubMed Web of Science ®Google Scholar
• Vellani V, Mapplebeck S, Moriondo A, Protein kinase C activation potentiates gating of the vanilloid receptor VR1 by capsaicin, protons, heat, and anandamide. J Physiol 2001;534:813-25
   PubMed Web of Science ®Google Scholar
• Bhave G, Zhu W, Wang H, cAMP-dependent protein kinase regulates desensitization of the capsaicin receptor (VR1) by direct phosphorylation. Neuron 2002;35:721-31
   PubMed Web of Science ®Google Scholar
• Prescott ED, Julius D. A modular PIP2 binding site as a determinant of capsaicin receptor sensitivity. Science 2003;300:1284-8
   PubMed Web of Science ®Google Scholar
• Chuang HH, Prescott ED, Kong H, Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4,5)P2-mediated inhibition. Nature 2001;411:957-62
   PubMed Web of Science ®Google Scholar
• Shin HJ, Gye MH, Chung KH, Activity of protein kinase C modulates the apoptosis induced by polychlorinated biphenyls in human leukemic HL-60 cells. Toxicol Lett 2002;135:25-31
   PubMed Web of Science ®Google Scholar
• Gavva NR, Treanor JJS, Garami A, Pharmacological blockade of the vanilloid receptor TRPv1 elicits marked hyperthermia in humans. Pain 2008;136(1-2):202-10
   PubMed Web of Science ®Google Scholar
• Rowbotham MC, Nothaft W, Duan WR, Oral and cutaneous thermosensory profile of selective TRPv1 inhibition by ABT-102 in a randomized healthy volunteer trial. Pain 2011. [Epub ahead of print]
   Web of Science ®Google Scholar
• Wong GY, Gavva NR. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: Recent advances and setbacks. Brain Res Rev 2009;60(1):267-77
   PubMed Web of Science ®Google Scholar
• Remadevi R, Szallisi A. Adlea (ALGRX-4975), an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief. IDrugs 2008;11(2):120-32
   PubMed Web of Science ®Google Scholar
• Irving GA, Backonja MM, Dunteman E, A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Pain Med 2011;12(1):99-109
   PubMed Web of Science ®Google Scholar
• Szallasi A, Blumberg PM. Resiniferatoxin, a phorbol-related diterpene, acts as an ultrapotent analog of capsaicin, the irritant constituent in red pepper. Neuroscience 1989;30(2):515-20
   PubMed Web of Science ®Google Scholar
• Peng CH, Kuo HC. Multiple intravesical instillations of low-dose resiniferatoxin in the treatment of refractory interstitial cystitis. Urol Int 2007;78(1):78-81
   PubMed Web of Science ®Google Scholar
• Priest BT. Future potential and status of selective sodium channel blockers for the treatment of pain. Curr Opin Drug Discov Dev 2009;12(5):682-92
   PubMed Web of Science ®Google Scholar
• Pezet S, McMahon SB. Neurotrophins: mediators and modulators of pain. Annu Rev Neurosci 2006;29:507-38
   PubMed Web of Science ®Google Scholar
• Delcroix JD, Valletta JS, Wu C, NGF signaling in sensory neurons: evidence that early endosomes carry NGF retrograde signals. Neuron 2003;3(39):69-84
   Google Scholar
• Shu XQ, Mendell LM. Acute sensitization by NGF of the response of small-diameter sensory neurons to capsaicin. J Neurophysiol 2001;86:2931-8
   PubMed Web of Science ®Google Scholar
• Bonnington JK, McNaughton PA. Signalling pathways involved in the sensitization of mouse nociceptive neurons by nerve growth factor. J Physiol 2003;551:433-46
   PubMed Web of Science ®Google Scholar
• Zhang X, Huang J, McNaughton PA. NGF rapidly increases membrane expression of TRPV1 heat-gated ion channels. EMBO J 2005;24:4211-23
   PubMed Web of Science ®Google Scholar
• Ji RR, Samad TA, Jin SX, p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia.Neuron 2002;36:57-68
   PubMed Web of Science ®Google Scholar
• Nicol GD, Vasko MR. Unraveling the story of NGF-mediated sensitization of nociceptive sensory neurons: on or off the Trks? Mol Interv 2007;7(1):26-41
   PubMedGoogle Scholar
• Chao MV. Neurotrophins and their receptors: a convergence point for many signaling pathways. Nat Rev Neurosci 2003;4:299-309
   PubMed Web of Science ®Google Scholar
• Crowley C, Spencer SD, Nishimura MC, Mice lacking nerve growth factor display perinatal loss of sensory and sympathetic neurons yet develop basal forebrain cholinergic neurons. Cell 1994;76(6):1001-11
   PubMed Web of Science ®Google Scholar
• Smeyne RJ, Klein R, Schnapp A, Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk/NGF receptor gene. Nature 1994;368(6468):246-9
   PubMed Web of Science ®Google Scholar
• Davis BM, Lewin GR, Mendell LM, Altered expression of nerve growth factor in the skin of transgenic mice leads to changes in response to mechanical stimuli. Neuroscience 1993;56(4):789-92
   PubMed Web of Science ®Google Scholar
• Stucky CL, Koltzenburg M, Schneider M, Overexpression of nerve growth factor in skin selectively affects the survival and functional properties of nociceptors. J Neurosci 1999;19(19):8509-16
   PubMed Web of Science ®Google Scholar
• Lewin GR, Ritter AM, Mendell LM. Nerve growth factor-induced hyperalgesia in the neonatal and adult rat. J Neurosci 1993;13(5):2136-48
   PubMed Web of Science ®Google Scholar
• Andreev NYU, Dimitrieva N, Koltzenburg M, Peripheral administration of nerve growth factor in the adult rat produces a thermal hyperalgesia that requires the presence of sympathetic post-ganglionic neurones. Pain 1995;63(1):109-15
   PubMed Web of Science ®Google Scholar
• Wild KD, Bian D, Zhu D, Antibodies to nerve growth factor reverse established tactile allodynia in rodent models of neuropathic pain without tolerance. J Pharmacol Exp Ther 2007;222(1):282-7
   Google Scholar
• Tonoki H, Awaya Y, Matsuda I. Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis. Nat Genet 1996;13:485-8
   PubMed Web of Science ®Google Scholar
• Friess H, Zhu ZW, di Mola FF, Nerve growth factor and its high-affinity receptor in chronic pancreatitis. Ann Surg 1999;230(5):615-24
   PubMed Web of Science ®Google Scholar
• Sarchielli P, Alberti A, Floridi A, Levels of nerve growth factor in cerebrospinal fluid of chronic daily headache patients. Neurology 2001;57(1):132-4
   PubMed Web of Science ®Google Scholar
• Rukwied R, Mayer A, Kluschina O, NGF induces non-inflammatory localized and lasting mechanical and thermal hypersensitivity in human skin. Pain 2010;148(3):407-13
   PubMed Web of Science ®Google Scholar
• Svensson P, Cairns BE, Wang K, Injection of nerve growth factor into human masseter muscle evokes long-lasting mechanical allodynia and hyperalgesia. Pain 2003;104(1-2):241-7
   PubMed Web of Science ®Google Scholar
• Wozney JM. Bone morphogenetic proteins. Prog Growth Factor Res 1989;1(4):267-80
   PubMedGoogle Scholar
• Chubinskaya S, Merrihew C, Cs-Szabo G, Human articular chondrocytes express osteogenic protein-I. J Histochem Cytochem 2000;48(2):239-50
   PubMed Web of Science ®Google Scholar
• Huch K, Wilbrink B, Flechtenmacher J, Effects of recombinant human osteogenic protein1 on the production of proteoglycan, prostaglandin E2, and interleukin-I receptor antagonist by human articular chondrocytes cultured in the presence of interleukin-1. Arthritis Rheum 1997;40:2157-61
   PubMed Web of Science ®Google Scholar
• Koepp HE, Sampath KT, Kuettner KE, Osteogenic protein-1 (OP-I) blocks cartilage damage caused by fibronectin fragments and promotes repair by enhancing proteoglycan synthesis. Inflamm Res 1999;47:1-6
   Google Scholar
• Elshaier AM, Hakimiyan AA, Rappoport L, Effect of interleukin-1beta on osteogenic protein 1-induced signaling in adult human articular chondrocytes. Arthritis Rheum 2009;60(1):143-54
   PubMed Web of Science ®Google Scholar
• Chubinskaya S, Kumar B, Merrihew C, Age-related changes in cartilage endogenous osteogenic protein-1 (OP-1). Biochim Biophys Acta 2002;1588:126-34
   PubMed Web of Science ®Google Scholar
• Loeser RF, Im HJ, Richardson B, Methylation of the OP-1 promoter: potential role in the age-related decline in OP-1 expression in cartilage. Osteoarthritis Cartilage 2009;17(4):513-17
   PubMed Web of Science ®Google Scholar
• Ellsworth JL, Berry J, Bukowski T, Fibroblast growth factor-18 is a trophic factor for mature chondrocytes and their progenitors. Osteoarthritis Cartilage 2002;10:308-20
   PubMed Web of Science ®Google Scholar
• Davidson D, Blanc A, Filion D, Fibroblast growth factor (FGF) 18 signals through FGF receptor 3 to promote chondrogenesis. J Biol Chem 2005;280:20509-15
   PubMed Web of Science ®Google Scholar
• Sandell LJ, Xing X, Franz C, Exuberant expression of chemokine genes by adult human articular chondrocytes in response to IL-1beta. Osteoarthritis Cartilage 2008;16(12):1560-71
   PubMed Web of Science ®Google Scholar
• Elluru RG, Thompson F, Reece A. Fibroblast growth factor 18 gives growth and directional cues to airway cartilage. Laryngoscope 2009;119(6):1153-65
   PubMed Web of Science ®Google Scholar
• Moore EE, Bendele AM, Thompson DL, Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis. Osteoarthritis Cartilage 2005;13:623
   PubMed Web of Science ®Google Scholar
• Naot D, Cornish J. The role of peptides and receptors of the calcitonin family in the regulation of bone metabolism. Bone 2008;43(5):813-18
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Sondergaard BC, Arnold M, Calcitonin affects both bone and cartilage: a dual action treatment for osteoarthritis? Ann N Y Acad Sci 2007;1117:181-95
   PubMed Web of Science ®Google Scholar
• Sondergaard BC, Wulf H, Henriksen K, Calcitonin directly attenuates collagen type II degradation by inhibition of matrix metalloproteinase expression and activity in articular chondrocytes. Osteoarthritis Cartilage 2006;14(8):759-68
   PubMed Web of Science ®Google Scholar
• Nielsen RH, Bay-Jensen AC, Byrjalsen I, Oral salmon calcitonin reduces cartilage and bone pathology in an osteoarthritis rat model with increased subchondral bone turnover. Osteoarthritis Cartilage 2011. [Epub ahead of print]
   Google Scholar
• Hardingham TE, Fosang AF, Dudiah J. Aggrecan, the chondroitin sulfate/keratan sulfate proteoglycan from cartilage. In: Kuettner KE, Schleyerback R, Peyron JG, , editors, Articular cartilage and osteoarthritis. Raven Press, New York; 1992. p. 6
   Google Scholar
• Wildi LM, Raynauld JP, Martel-Pelletier J, Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Ann Rheum Dis 2011. [Epub ahead of print]
   Web of Science ®Google Scholar
• Kahan A, Uebelhart D, De Vathaire F, Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009;60(2):524-33
   PubMed Web of Science ®Google Scholar
• Michel BA, Stucki G, Frey D, Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum 2005;52(3):779-86
   PubMed Web of Science ®Google Scholar
• Moller I, Perez M, Monfort J, Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double-blind, placebo-controlled study. Osteoarthritis Cartilage 2010;18(Suppl 1):S32-40
   PubMedGoogle Scholar
• Hochberg MC. Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration. Osteoarthritis Cartilage 2010;18 (Suppl 1):S28-31
   PubMed Web of Science ®Google Scholar
• Lee YH, Woo JH, Choi SJ, Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis. Rheumatol Int 2010;30(3):357-63
   PubMed Web of Science ®Google Scholar
• Abramson SB, Amin AR, Clancy RM, The role of nitric oxide in tissue destruction. Best Pract Res Clin Rheumatol 2001;15:831-45
   PubMed Web of Science ®Google Scholar
• Pelletier JP, Jovanovic D, Lascau-Coman V, Fernandes JC, Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase. Arthritis Rheum 1998;41:1275-86
   PubMed Web of Science ®Google Scholar
• Pelletier JP, Lascau-Coman V, Jovanovic D, Selective inhibition of iNOS in experimental OA is associated with reduction in tissue levels of catabolic factors. J Rheumatol 1999;26(9):2002-14
   PubMed Web of Science ®Google Scholar
• Pelletier J-P, Jovanovic DV, Lascau-Coman V, Selective inhibition of inducible nitric oxide synthase reduces progression of experimental osteoarthritis in vivo: possible link with the reduction in chondrocyte apoptosis and caspase 3 level. Arthritis Rheum 2000;43:1290-9
   PubMed Web of Science ®Google Scholar
• Bijlsma JWJ, Welsing PMJ. The art of medicine in treating osteoarthritis: I will please. Ann Rheum Dis 2008;67:1653-5
   PubMed Web of Science ®Google Scholar
• Bingham CO III, Buckland-Wright JC, Garnero P, Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 2006;54(11):3494-507
   PubMed Web of Science ®Google Scholar
• Mazzuca SA, Brandt KD, Chakr R, Varus malalignment negates the structure-modifying benefits of doxycycline in obese women with knee osteoarthritis. Osteoarthritis Cartilage 2010;18(8):1008-11
   PubMed Web of Science ®Google Scholar